<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348868</url>
  </required_header>
  <id_info>
    <org_study_id>A007</org_study_id>
    <nct_id>NCT00348868</nct_id>
  </id_info>
  <brief_title>Buprenorphine HIV Care Integration Project</brief_title>
  <official_title>Miami Buprenorphine HIV Care Integration Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HRSA/Maternal and Child Health Bureau</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A007 is a randomized, two-arm study evaluating the effectiveness of standard drug addiction
      counseling with buprenorphine/naloxone to enhanced motivational drug counseling with
      buprenorphine/naloxone for the treatment for opioid addiction in an integrated and
      nonintegrated HIV care setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN: A007 is a randomized, two-arm study evaluating the effectiveness of standard drug
      addiction counseling with buprenorphine/naloxone to enhanced motivational drug counseling
      with buprenorphine/naloxone for the treatment for opioid addiction in an integrated and
      nonintegrated HIV care setting.

      DURATION: Subjects will participate in this study for approximately 48 weeks. Chart
      abstractions will continue for up to four years.

      SAMPLE SIZE: This study will enroll 60 subjects (30 per arm) over 72 weeks.

      POPULATION: HIV-1 infected opioid dependent men and women ≥18 years of age who initiate
      buprenorphine for the treatment of opioid dependence and who are receiving primary care for
      HIV-1 infection.

      STRATIFICATION: Subjects will be stratified at screening based on HIV care setting
      (integrated HIV care vs. nonintegrated HIV care)

      INTERVENTON At entry subjects will be randomized to one of the following:

      ARM A: Standard drug addiction counseling + buprenorphine / naloxone

      ARM B: Enhanced behavioral motivation counseling + buprenorphine / naloxone

      The three primary outcomes are:

        1. Cessation of illicit opioid use

        2. Reduction in high risk behavior

        3. Improved HIV therapy adherence
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The three primary outcomes are Cessation of illicit opioid use, Reduction in high risk behavior and Improved HIV therapy adherence</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV Infection</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enhanced behavioral motivation counseling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>enhanced behavioral motivation counseling</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational counseling</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard counseling</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Receiving or seeking outpatient HIV care

          -  Seeking outpatient treatment for opioid dependence and be willing to take
             buprenorphine

          -  Meets DSM-IV criteria for opioid dependence, and be willing to stop illicit opioid use
             and be experiencing early symptoms of opioid withdrawal at the time that buprenorphine
             is given

          -  Men and women age ≥ 18 years

          -  Women of reproductive potential must have a negative serum or urine pregnancy test
             result available within 7 days prior to initiating buprenorphine

          -  Within 30 days: (SGOT), ALT (SGPT), and alkaline phosphatase &lt;=5 X ULN, Total
             bilirubin &lt;= 2.5 x ULN

        Exclusion Criteria:

          -  Serious medical problem

          -  Acute and/or severe psychiatric conditions

          -  High dose methadone (&gt;30 mg/day)

          -  Documented co-dependence on alcohol and/or benzodiazepines, barbiturates

          -  Chronic pain management requiring opioids

          -  Pregnancy or breast-feeding

          -  Imprisonment or involuntary incarceration in a medical facility for psychiatric or
             physical
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Fischl, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami AIDS Clinical Reserach Unit</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2006</study_first_submitted>
  <study_first_submitted_qc>July 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2006</study_first_posted>
  <last_update_submitted>March 14, 2008</last_update_submitted>
  <last_update_submitted_qc>March 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Margaret A. Fischl, M.D.</name_title>
    <organization>Unversity of Miami</organization>
  </responsible_party>
  <keyword>HIV Infection</keyword>
  <keyword>Opioid dependence</keyword>
  <keyword>DSM-IV criteria for opioid dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

